A

Alliance Pharma PLC
LSE:APH

Watchlist Manager
Alliance Pharma PLC
LSE:APH
Watchlist
Price: 64.2 GBX
Market Cap: 347m GBX
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one APH stock under the Base Case scenario is 92.32 GBX. Compared to the current market price of 64.2 GBX, Alliance Pharma PLC is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

APH Relative Value
Base Case
92.32 GBX
Undervaluation 30%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
58
vs Industry
52
Median 3Y
1.6
Median 5Y
2.2
Industry
2.4
Forward
1.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
1
Median 3Y
-7.1
Median 5Y
15.3
Industry
20.5
Forward
14.3
More Details
11.5
P/OCF
P/OCF
Price to OCF
11.5
vs History
46
vs Industry
34
Median 3Y
9.3
Median 5Y
11.4
Industry
15.4
More Details
83.3
P/FCFE
P/FCFE
Price to FCFE
83.3
vs History
0
vs Industry
6
Median 3Y
37
Median 5Y
33.4
Industry
22.8
More Details
1.6
P/B
P/B
Price to Book Value
1.6
vs History
33
vs Industry
47
Median 3Y
1.1
Median 5Y
1.4
Industry
1.9
More Details
2.4
EV/S
EV/S
Enterprise Value to Sales
2.4
vs History
60
vs Industry
44
Median 3Y
2.2
Median 5Y
2.9
Industry
2.5
Forward
2.2
More Details
4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4
vs History
58
vs Industry
49
Median 3Y
3.8
Median 5Y
4.7
Industry
4.9
More Details
8.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.2
vs History
63
vs Industry
37
Median 3Y
7.9
Median 5Y
11.4
Industry
12.4
Forward
9.7
More Details
10.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.6
vs History
61
vs Industry
36
Median 3Y
10.2
Median 5Y
12.9
Industry
15.5
Forward
10.6
More Details
14.3
EV/OCF
EV/OCF
Enterprise Value to OCF
14.3
vs History
38
vs Industry
29
Median 3Y
12.6
Median 5Y
13.3
Industry
14
More Details
14.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
14.9
vs History
50
vs Industry
26
Median 3Y
12.7
Median 5Y
15
Industry
17.9
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
30
vs Industry
51
Median 3Y
0.9
Median 5Y
1.2
Industry
1.8
More Details

Multiples Across Competitors

APH Competitors Multiples
Alliance Pharma PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Alliance Pharma PLC
LSE:APH
347m GBP 1.9 -10.3 8.2 10.6
US
Eli Lilly and Co
NYSE:LLY
714.2B USD 15.9 67.4 39.3 43.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
363.4B USD 4.1 25.8 12.1 15.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.5 18.8 12.4 14.1
CH
Roche Holding AG
SIX:ROG
196B CHF 3.3 17.1 9.6 11.4
US
Merck & Co Inc
NYSE:MRK
207.4B USD 3.2 12.1 8.2 9.7
CH
Novartis AG
SIX:NOVN
174.8B CHF 3.9 17.1 10.4 13.3
UK
AstraZeneca PLC
LSE:AZN
158.6B GBP 3.8 28.9 125.6 191.8
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
US
Pfizer Inc
NYSE:PFE
127.4B USD 2 15.9 7.9 11.2
P/E Multiple
Earnings Growth PEG
UK
A
Alliance Pharma PLC
LSE:APH
Average P/E: 25.4
Negative Multiple: -10.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67.4
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
25.8
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.8
19%
1
CH
Roche Holding AG
SIX:ROG
17.1
16%
1.1
US
Merck & Co Inc
NYSE:MRK
12.1
18%
0.7
CH
Novartis AG
SIX:NOVN
17.1
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.9
36%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
A
Alliance Pharma PLC
LSE:APH
Average EV/EBITDA: 394.5
8.2
5%
1.6
US
Eli Lilly and Co
NYSE:LLY
39.3
30%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.1
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
12.4
15%
0.8
CH
Roche Holding AG
SIX:ROG
9.6
8%
1.2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
125.6
9%
14
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.9
3%
2.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
A
Alliance Pharma PLC
LSE:APH
Average EV/EBIT: 1 697.7
10.6
10%
1.1
US
Eli Lilly and Co
NYSE:LLY
43.4
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.9
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.4
9%
1.3
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
CH
Novartis AG
SIX:NOVN
13.3
8%
1.7
UK
AstraZeneca PLC
LSE:AZN
191.8
21%
9.1
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
11.2
10%
1.1

See Also

Summary
APH intrinsic value, competitors valuation, and company profile.
DCF Valuation
APH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
APH stock valuation using valuation multiples.
Wall Street Estimates
APH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
APH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 245,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.